Atopic Dermatitis: Upadacitinib Effective in Two Phase 3 Trials Atopic Dermatitis: Upadacitinib Effective in Two Phase 3 Trials

The JAK inhibitor, currently approved for rheumatoid arthritis, yielded improvements in skin clearance, itch, and quality of life for nearly 1700 patients with moderate to severe disease.Medscape Medical News
Source: Medscape Dermatology Headlines - Category: Dermatology Tags: Dermatology News Source Type: news